Dr. Price co-founded 4E Therapeutics. He currently serves as the Eugene McDermott Endowed Professor and the Neuroscience Program Head at The University of Texas at Dallas (UTD). He is also the founder and director of the Center for Advanced Pain Studies at UTD. He graduated from UTD in 1998 as a Nortel Scholar with a B.S. in Neuroscience where he worked with Dr. Alice O’Toole on human face perception. He then received his PhD in 2003 from the University of Texas Health Science Center at San Antonio under the mentorship of Christopher Flores and Kenneth Hargreaves where he worked on cannabinoid pharmacology and pain. He was then a postdoctoral fellow in the laboratory of Fernando Cervero at McGill University until 2007 where he developed the first studies on how local control of protein synthesis in neurons is involved in the development of chronic pain disorders.
Dr. Price was a faculty member of The University of Arizona School of Medicine from 2007-2014 where he further developed work on nervous system plasticity in relation to pain with funding from the National Institutes of Health (NIH)-, Rita Allen Foundation- and Migraine Research Foundation. Dr. Price is the recipient of Young Investigator Awards from the American Pain Society and International Association for the Study of Pain (IASP), has published more than 110 peer-reviewed articles in international journals, serves as the neurobiology section editor for Painand is on the editorial board for Journal of Neuroscience, Pain, Molecular Pain and The European Journal of Neuroscience. He is also a regular member of the Somatosensory and Pain Study Section for the National Institutes of Health and a regular grant reviewer for American Pain Society and IASP study sections. He currently holds 3 NIH R01s that fund his academic work at UTD.
In addition to this academic activity, Dr. Price is a founder of 3 companies in the pain therapeutics space. In 2015 he co-founded both Ted’s Brain Science Products and CerSci Therapeutics. Ted’s Brain Science Products developed a topical pain therapeutic that has been on the OTC market since 2016. CerSci Therapeutics developed a novel approach for post-surgical pain, which was supported by a Direct to Phase II SBIR and this molecule is now IND approved and beginning Phase I clinical trials. He is driven to develop new therapeutics for neuropathic pain, leading to the formation of 4E Therapeutics.